Wells Fargo
DNTH icon

Wells Fargo’s Dianthus Therapeutics DNTH Stock Holding History

Wells Fargo’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Sell
13,787
-15,181
-52% -$879K ﹤0.01% 3658
2025
Q4 		$1.19M Buy
28,968
+16,585
+134% +$643K ﹤0.01% 3834
2025
Q3 		$487K Buy
12,383
+57
+0.5% +$1.46K ﹤0.01% 4323
2025
Q2 		$230K Sell
12,326
-3,053
-20% -$57.3K ﹤0.01% 4696
2025
Q1 		$279K Buy
15,379
+1,561
+11% +$34.4K ﹤0.01% 4470
2024
Q4 		$301K Sell
13,818
-8,271
-37% -$213K ﹤0.01% 4521
2024
Q3 		$605K Buy
22,089
+11,770
+114% +$328K ﹤0.01% 3871
2024
Q2 		$267K Buy
10,319
+10,095
+4,507% +$243K ﹤0.01% 4319
2024
Q1 		$6.72K Buy
224
+150
+203% +$3.26K ﹤0.01% 5835
2023
Q4 		$769 Buy
74
+24
+48% +$265 ﹤0.01% 6290
2023
Q3 		$684 Buy
50
+1
+2% +$13 ﹤0.01% 6292
2023
Q2 		$591 Buy
49
+1
+2% +$11 ﹤0.01% 6451
2023
Q1 		$608 Hold
48
– – ﹤0.01% 6505
2022
Q4 		$300 Sell
48
-92
-66% -$1.63K ﹤0.01% 6509
2022
Q3 		$3K Sell
140
-210
-60% -$5.75K ﹤0.01% 6042
2022
Q2 		$7K Buy
350
+244
+230% +$6.03K ﹤0.01% 5879
2022
Q1 		$5K Sell
106
-663
-86% -$36.2K ﹤0.01% 6467
2021
Q4 		$54K Sell
769
-972
-56% -$97.7K ﹤0.01% 5932
2021
Q3 		$203K Buy
1,741
+1,712
+5,903% +$199K ﹤0.01% 5085
2021
Q2 		$4K Sell
29
-133
-82% -$24.4K ﹤0.01% 6391
2021
Q1 		$30K Sell
162
-975
-86% -$164K ﹤0.01% 6031
2020
Q4 		$143K Buy
1,137
+394
+53% +$44.7K ﹤0.01% 5215
2020
Q3 		$81K Sell
743
-1
-0.1% -$118 ﹤0.01% 5339
2020
Q2 		$89K Sell
744
-469
-39% -$66.1K ﹤0.01% 5272
2020
Q1 		$122K Sell
1,213
-46
-4% -$8.52K ﹤0.01% 4960
2019
Q4 		$306K Sell
1,259
-882
-41% -$165K ﹤0.01% 4713
2019
Q3 		$352K Buy
2,141
+265
+14% +$50.3K ﹤0.01% 4608
2019
Q2 		$443K Buy
1,876
+1,345
+253% +$333K ﹤0.01% 4457
2019
Q1 		$140K Buy
531
+493
+1,297% +$85.1K ﹤0.01% 4996
2018
Q4 		$3K Buy
38
+2
+6% +$273 ﹤0.01% 6137
2018
Q3 		$7K Buy
+36
New +$7.58K ﹤0.01% 6055

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wells Fargo's DNTH Position: Q1 2026 in Review

Wells Fargo reduced its Dianthus Therapeutics (DNTH) stake by 52% in Q1 2026, selling an estimated $879K and leaving 13,787 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

Wells Fargo first reported a position in DNTH in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.19M in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Wells Fargo held 13,787 shares of Dianthus Therapeutics worth $1.16M as of Q1 2026.
  • Wells Fargo sold 15,181 Dianthus Therapeutics shares in Q1 2026, an estimated $879K.
  • Dianthus Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3658 holding.
  • Wells Fargo first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • Wells Fargo's Dianthus Therapeutics position peaked at $1.19M in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.